DB
AMLX icon

Dmitry Balyasny’s Amylyx Pharmaceuticals AMLX Stock Holding History

Dmitry Balyasny’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-425,000
Closed -$9.17M – 2224
2023
Q2 		$9.17M Buy
+425,000
New +$11.5M 0.02% 827

Other funds holding AMLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Dmitry Balyasny's AMLX Position: Q2 2026 in Review

Dmitry Balyasny reduced its Amylyx Pharmaceuticals (AMLX) stake by 38% in Q2 2026, selling an estimated $6.53M and leaving 684,974 shares worth $12.3M. The position accounts for 0.02% of the portfolio, ranked #966.

Dmitry Balyasny first reported a position in AMLX in Q1 2022 and has held it in 15 quarters since. The position peaked at $25.3M in Q2 2023. 205 funds tracked by Wall St. Rank hold AMLX as of Q2 2026.

  • Dmitry Balyasny held 684,974 shares of Amylyx Pharmaceuticals worth $12.3M as of Q2 2026.
  • Dmitry Balyasny sold 422,297 Amylyx Pharmaceuticals shares in Q2 2026, an estimated $6.53M.
  • Amylyx Pharmaceuticals made up 0.02% of Dmitry Balyasny's portfolio in Q2 2026, its #966 holding.
  • Dmitry Balyasny first reported a position in Amylyx Pharmaceuticals in Q1 2022 and has held it in 15 quarters since.
  • Dmitry Balyasny's Amylyx Pharmaceuticals position peaked at $25.3M in Q2 2023.
  • 205 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q2 2026.

Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.